Antibody Bioavailability Protein 
The Pharma Data
APRIL 7, 2023
One of the greatest challenges in modern drug design is to find compounds that satisfy somewhat contradictory requirements – they need to be small enough to permeate human cell membranes, while being large enough to target various protein surfaces and protein–protein interactions.
Delveinsight
FEBRUARY 16, 2021
Padcev is a first-in-class antibody-drug conjugate (ADC) directed against Nectin-4, a protein. The therapy is the first therapy of its kind to target the Nectin-4 protein. Maribavir is an orally bioavailable anti-CMV compound. located on the surface of cells and highly expressed in bladder cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
AUGUST 16, 2021
Lebrikizumab is a novel monoclonal antibody (mAb) that binds soluble IL-13 with high affinity, has high bioavailability, a long half-life and blocks IL-13 signaling. “Lebrikizumab is a specific inhibitor of IL-13 that offers robust binding affinity and high bioavailability. 1-4 The U.S. About Lebrikizumab.
Delveinsight
SEPTEMBER 8, 2021
Baricitinib, also known as LY3009104 or INCB028050 , is a novel orally bioavailable inhibitor of the tyrosine-protein kinase JAK1 or JAK2. percent ) who were anti-dsDNA autoantibody-positive (“Antibody Positive”). Currently, the SLE therapeutics market is revolving around only one drug i.e Baricitinib (INCB-028050).
XTalks
AUGUST 30, 2022
A major obstacle for CNS drug developers is the inability to target therapies to the CNS broadly (for instance, a therapy that is orally bioavailable as a pill and has difficulty crossing the blood-brain barrier) and certain CNS regions more specifically. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets?
XTalks
AUGUST 8, 2024
Antibody-drug conjugates (ADCs) are at the forefront of targeted cancer therapy. They combine the precision of monoclonal antibodies (mAbs) with the potency of cytotoxic drugs to destroy cancer cells, without harming healthy tissue. For the antibody component, the specificity of tumor cells is paramount. “We
Delveinsight
AUGUST 25, 2020
The drug, Spartalizumab, is an experimental monoclonal antibody designed as immunotherapy to target the human programmed death-1 (PD-1) receptor. The drug is directly delivered to lungs via inhalation to achieve high local exposures, and address the concerns of low oral bioavailability linked to niclosamide. .
Expert insights. Personalized for you.
40 
Let's personalize your content